BRPI0515516B8 - - Google Patents

Info

Publication number
BRPI0515516B8
BRPI0515516B8 BRPI0515516A BRPI0515516B8 BR PI0515516 B8 BRPI0515516 B8 BR PI0515516B8 BR PI0515516 A BRPI0515516 A BR PI0515516A BR PI0515516 B8 BRPI0515516 B8 BR PI0515516B8
Authority
BR
Brazil
Application number
Other languages
Portuguese (pt)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515516(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0421079A external-priority patent/GB0421079D0/en
Priority claimed from GB0421078A external-priority patent/GB0421078D0/en
Priority claimed from GB0421081A external-priority patent/GB0421081D0/en
Priority claimed from GB0421082A external-priority patent/GB0421082D0/en
Priority claimed from GB0503143A external-priority patent/GB0503143D0/en
Application filed filed Critical
Priority to BR122016029840-0A priority Critical patent/BR122016029840B1/pt
Publication of BRPI0515516A publication Critical patent/BRPI0515516A/pt
Publication of BRPI0515516B1 publication Critical patent/BRPI0515516B1/pt
Publication of BRPI0515516B8 publication Critical patent/BRPI0515516B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0515516-9A 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition. BRPI0515516B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0421079A GB0421079D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421079.5 2004-09-22
GB0421078A GB0421078D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421081A GB0421081D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421082.9 2004-09-22
GB0421081.1 2004-09-22
GB0421078.7 2004-09-22
GB0421082A GB0421082D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0503143A GB0503143D0 (en) 2005-02-15 2005-02-15 Immunogenic composition
GB0503143.0 2005-02-15
PCT/EP2005/010184 WO2006032472A2 (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei

Publications (3)

Publication Number Publication Date
BRPI0515516A BRPI0515516A (pt) 2008-07-29
BRPI0515516B1 BRPI0515516B1 (pt) 2017-08-08
BRPI0515516B8 true BRPI0515516B8 (https=) 2021-05-25

Family

ID=36000843

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0515516-9A BRPI0515516B1 (pt) 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica

Country Status (17)

Country Link
US (6) US20080085289A1 (https=)
EP (9) EP2305295B1 (https=)
JP (5) JP2008513409A (https=)
KR (4) KR20070058631A (https=)
CN (2) CN102657855B (https=)
AU (3) AU2005287532B2 (https=)
BR (3) BRPI0515516B1 (https=)
CA (4) CA2983954C (https=)
ES (4) ES2472441T3 (https=)
IL (4) IL181825A0 (https=)
MA (2) MA28995B1 (https=)
MX (2) MX2007003400A (https=)
NO (2) NO20071609L (https=)
NZ (4) NZ593693A (https=)
RU (1) RU2402347C2 (https=)
WO (3) WO2006032472A2 (https=)
ZA (1) ZA200702224B (https=)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
EP1812066A4 (en) * 2004-10-25 2010-06-30 Univ Western Ontario STAINLOCOCCUS AUREUS-BASED ANTI-INFECTION AGENTS ON ISD PROTEIN
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US8398983B2 (en) * 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
BRPI0710889A2 (pt) * 2006-04-24 2011-08-16 Sigma Alimentos Sa De Cv método para a detecção e quantificação múltipla e simultánea de patogênicos mediante a reação em cadeia da polimerasa em tempo real
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
EP2043690A1 (en) * 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
WO2009023164A2 (en) * 2007-08-10 2009-02-19 President And Fellows Of Harvard College Induction of mucosal immunity
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
CN101981452B (zh) * 2008-03-31 2017-05-17 大塚制药株式会社 肺炎球菌检测方法
AU2009237648A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US8318180B2 (en) * 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
HUE036372T2 (hu) * 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1011753B8 (pt) * 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP6091214B2 (ja) * 2009-11-16 2017-03-08 ザ ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレイティド ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
MX2012006961A (es) 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
DK2560738T3 (da) 2010-04-23 2019-08-26 Serum Inst India Ltd Simpel fremgangsmåde til samtidig fjernelse af flere urenheder fra dyrkningssupernatanter til ultralave niveauer
CN102268444B (zh) * 2010-06-03 2015-05-13 中国人民解放军军事医学科学院生物工程研究所 金黄色葡萄球菌截短SasA蛋白在大肠杆菌中的表达及应用
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012009247A1 (en) * 2010-07-15 2012-01-19 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus protein sa2412
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
DK2654784T3 (en) * 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
EP3470526A3 (en) * 2011-02-08 2019-07-17 Medimmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
AU2012273125B2 (en) 2011-06-19 2017-05-25 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide
MX357938B (es) * 2011-06-19 2018-07-31 Univ New York Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
EP2773370A4 (en) 2011-10-31 2016-09-28 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2451
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
BR112014027818B1 (pt) * 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
WO2013184900A2 (en) * 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
CN102898511B (zh) * 2012-10-19 2014-05-07 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法
CN103087198B (zh) * 2013-01-21 2014-03-12 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原i1c及制备方法和应用
JP6411378B2 (ja) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
CN103333254A (zh) * 2013-06-21 2013-10-02 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）重组蛋白疫苗i1c的纯化方法
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
CN105483138B (zh) * 2016-01-22 2019-03-26 吉林大学 一种与致病力相关的灰霉病菌基因BcAtm1及其应用
WO2017137954A2 (en) * 2016-02-12 2017-08-17 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
CN109922828A (zh) * 2016-10-20 2019-06-21 Km生物医药股份公司 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
ES2985591T3 (es) 2018-02-12 2024-11-06 Inimmune Corp Ligandos de receptores tipo Toll
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN109395072B (zh) * 2018-10-30 2021-11-30 中国兽医药品监察所 一种腐败梭菌α毒素基因工程疫苗及其生产方法
CN110055276A (zh) * 2019-01-28 2019-07-26 杨凌职业技术学院 一种金葡菌靶向抗菌肽细菌诱导型表达载体及其重组细胞
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
CN110892989B (zh) * 2019-06-27 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解便秘功能的副干酪乳杆菌et-22
CN112391304B (zh) * 2019-08-15 2023-04-07 上海交通大学 副血链球菌f278及其用途
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN110590910A (zh) * 2019-09-27 2019-12-20 黑龙江八一农垦大学 能够增强细胞免疫应答和抗感染作用的合成肽
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
JP2023512215A (ja) * 2020-01-29 2023-03-24 ザ ジャクソン ラボラトリー 細菌混和物
KR20230098825A (ko) 2020-11-04 2023-07-04 엘리고 바이오사이언스 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB116556A (en) 1917-06-21 1918-06-20 British Thomson Houston Co Ltd Improvements in and relating to Dynamo Electric Machines.
SE335780B (https=) * 1964-09-14 1971-06-07 Canadian Patents Dev
FR2227861B1 (https=) * 1973-05-04 1976-07-02 Anvar
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE162219T1 (de) 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
DE69233012T2 (de) * 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
ATE300617T1 (de) 1993-02-05 2005-08-15 Smithkline Beecham Plc Fibronektinbindungsprotein, monoklonaler antikoerper und ihre verwendung zur verhuetung der adhäsion von bakterien
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2158733C (en) 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
EP0914178B1 (en) 1996-06-18 2003-03-12 Alza Corporation Device for enhancing transdermal agent delivery or sampling
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU722574B2 (en) 1996-12-20 2000-08-10 Alza Corporation Device and method for enhancing transdermal agent flux
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1096952B1 (en) * 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
KR100644953B1 (ko) 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
EP1117772B1 (en) 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPEUTICS AGAINST STAPHYLOCOCCUS USING DONOR SELECTION AND DONOR STIMULATION
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
AU6033299A (en) 1998-09-14 2000-04-03 Nabi Compositions of beta-glucans and specific igiv
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP4424984B2 (ja) * 2001-06-15 2010-03-03 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
EP1412379B1 (en) 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
AU2003216487A1 (en) 2002-03-05 2003-09-22 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AU2009237648A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
DK2654784T3 (en) 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES

Also Published As

Publication number Publication date
EP2893938B1 (en) 2019-03-06
ES2472441T3 (es) 2014-07-01
EP1793849A2 (en) 2007-06-13
BR122016029840B1 (pt) 2021-10-13
KR101359930B1 (ko) 2014-02-12
EP2298340B1 (en) 2014-04-16
CA2983954A1 (en) 2006-03-30
JP2012107028A (ja) 2012-06-07
JP2008513406A (ja) 2008-05-01
CA2983954C (en) 2019-09-17
CN102657855B (zh) 2015-12-09
IL181920A (en) 2014-12-31
BRPI0515516A (pt) 2008-07-29
NZ582441A (en) 2011-09-30
NZ553776A (en) 2010-05-28
MA28994B1 (fr) 2007-11-01
AU2005287502B2 (en) 2011-12-01
IL181920A0 (en) 2011-07-31
MX2007003402A (es) 2007-05-10
EP2181714A2 (en) 2010-05-05
KR20070058631A (ko) 2007-06-08
KR101505496B1 (ko) 2015-03-25
EP2181714A3 (en) 2010-06-23
US20150328302A1 (en) 2015-11-19
IL181825A0 (en) 2007-07-04
KR101508563B1 (ko) 2015-04-07
JP6594385B2 (ja) 2019-10-23
CN102657855A (zh) 2012-09-12
ES2540771T3 (es) 2015-07-13
AU2005287502A1 (en) 2006-03-30
EP2305294A1 (en) 2011-04-06
JP2018048132A (ja) 2018-03-29
US20190076516A1 (en) 2019-03-14
NO20071610L (no) 2007-06-20
WO2006032475A2 (en) 2006-03-30
EP2305295B1 (en) 2015-04-01
CN101128215B (zh) 2012-10-10
EP1791559A2 (en) 2007-06-06
ES2730275T3 (es) 2019-11-11
RU2007110029A (ru) 2008-10-27
EP2298340A1 (en) 2011-03-23
US20110008385A1 (en) 2011-01-13
EP2305295A1 (en) 2011-04-06
US10548963B2 (en) 2020-02-04
EP2893938A1 (en) 2015-07-15
CA2584290A1 (en) 2006-03-30
WO2006032500A2 (en) 2006-03-30
US20080085289A1 (en) 2008-04-10
BRPI0515520A (pt) 2008-07-29
US20200179504A1 (en) 2020-06-11
WO2006032472A3 (en) 2006-07-20
CA2580103A1 (en) 2006-03-30
WO2006032472A2 (en) 2006-03-30
IL223141A0 (en) 2012-12-31
NZ553775A (en) 2010-05-28
JP5775005B2 (ja) 2015-09-09
CN101128215A (zh) 2008-02-20
EP2305296A1 (en) 2011-04-06
WO2006032475A3 (en) 2007-01-25
CA2580103C (en) 2021-11-16
US20080095777A1 (en) 2008-04-24
BRPI0515516B1 (pt) 2017-08-08
MX2007003400A (es) 2008-03-04
NZ593693A (en) 2013-08-30
JP2008513409A (ja) 2008-05-01
EP2305294B1 (en) 2015-04-01
HK1155658A1 (en) 2012-05-25
IL182639A0 (en) 2011-08-01
AU2005287532B2 (en) 2011-09-01
NO20071609L (no) 2007-06-18
IL223141B (en) 2018-06-28
WO2006032500A3 (en) 2006-06-22
MA28995B1 (fr) 2007-11-01
CA2580137A1 (en) 2006-03-30
JP2015166365A (ja) 2015-09-24
ES2540770T3 (es) 2015-07-13
KR20130087633A (ko) 2013-08-06
AU2005287505A1 (en) 2006-03-30
KR20120128724A (ko) 2012-11-27
ZA200702224B (en) 2016-09-28
AU2005287532A1 (en) 2006-03-30
KR20070054732A (ko) 2007-05-29
EP1804833A2 (en) 2007-07-11
RU2402347C2 (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
FR19C1052I1 (https=)
IN2014DN10699A (https=)
BRPI0515516B8 (https=)
ECSDI055539S (https=)
JP2005223582A5 (https=)
IN2006DE04099A (https=)
IN2006DE07971A (https=)
JP2005062188A5 (https=)
ECSDI055799S (https=)
JP2004228094A5 (https=)
JP2006029150A5 (https=)
JP2004239907A5 (https=)
JP2004246359A5 (https=)
JP2005065241A5 (https=)
JP2005282078A5 (https=)
JP2005196946A5 (https=)
CN300859090S (zh) 促销用装置
FR2849837A3 (https=)
FR2851493A3 (https=)
FR2848176A3 (https=)
FR2846849A3 (https=)
FR2843284A3 (https=)
ECSDI045326S (https=)
ECSDI044947S (https=)
FR2852340A3 (https=)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.